期刊文献+

TRAI联合吉西他滨体外诱导人肝内胆管细胞癌细胞凋亡作用的研究 被引量:2

下载PDF
导出
摘要 目的:探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)对人肝内胆管细胞癌细胞HCCC-9810的作用及联合化疗药物吉西他滨(GEM)共同作用人肝内胆管细胞癌细胞对TRAIL抗肿瘤活性的影响。方法:单独应用不同浓度TRAIL(10、30、100、300、1 000 ng/ml),不同浓度GEM(10、20、40、80μg/ml)及100 ng/ml TRAIL+GEM(10、20、40、80μg/ml)联合作用于人肝内胆管细胞癌细胞HCCC-9810,应用四氮唑蓝快速比色(MTT)进行检测,计算肿瘤细胞生长抑制率。结果:GEM与TRAIL联合应用对HCCC-9810细胞抑制率明显高于单独应用TRAIL和GEM(P<0.05)。结论:TRAIL通过诱导肝内胆管细胞癌细胞凋亡而起到抑癌作用,GEM能加强TRAIL的抗癌活性。
出处 《吉林医学》 CAS 2011年第4期694-695,共2页 Jilin Medical Journal
  • 相关文献

参考文献7

  • 1Wang P,Zhang J,Jiang W,et al.Inhibition of RIP and c-Flip enhances TRAIL-induced apoptosis in pancreatic cancer cells[J].Cellular Signaling,2007,19(12):2237.
  • 2Buchsbaum DJ,Zhou T,Lobuglio AF,et al.TRAIL receptor-targeted therapy[J].Future Oncol,2006,2(3):493.
  • 3Eggert A,Grozer MA,Zuzak TJ,et al.Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression[J].Cancer Res,2001,61(4):1314.
  • 4段永亮,王欣,李占飞,邹声泉.TRAIL抑制胆管癌细胞作用的研究[J].中华肝胆外科杂志,2003,9(12):728-728. 被引量:3
  • 5Langaas V,Shahzidi S,Johnsen J,et al.Interferon gamma modulates TRAIL mediated apoptosis in human colon carcinoma cells[J].Anticancer Res,2001,21(19):3733.
  • 6Hertel LW,Boder,Goin JS,et al.Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)[J].Cancer Res,1990,50(14):4417.
  • 7Bu HA,Moore M,Jndersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403.

二级参考文献1

共引文献2

同被引文献15

  • 1林俊,朱俊,黄世明.吉西他滨联合奥沙利铂治疗晚期肝内胆管细胞癌28例[J].肿瘤学杂志,2009,15(12):1118-1120. 被引量:2
  • 2郑晨宏,谢晓华.CIK细胞联合化疗对胃癌疗效的Meta分析[J].中国肿瘤生物治疗杂志,2015,22(3):363-368. 被引量:5
  • 3Khan S,Themas HC,Davidson BR,et al. Cholanglocarcinoma[ J]. Lancet,2005,366 (9493) : 1303 - 1304.
  • 4Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine ver- sus gemcitabine for biliary tract caner[ J]. N Engl J Med,2010, 362(14) :1273 - 1281.
  • 5Gurlevik E, Fleischmann - Mundt B, Armbrecbt N, et al. Adjuvant gemcltabine therapy improves survival in a locally induced, RO - resectable model of metastatic intrahepatic cholangiocarcinoma[ J ]. Hepatology, 2013,58 ( 3 ) : 1031 - 1041.
  • 6Kenya Yamanaka, Etsuro Hatano, Masashi Kanai, et al. A single - center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer [ J ]. Int J Clinical Oncol,2014,19(3) :485 -489.
  • 7Chigusa Morizane ,Takuji Okusaka, Junki Mizusawa, et al. Random- ized phase Ⅱ study of gemcitabine plus S - 1 versus S - 1 in ad- vanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805) [J]. Cancer Science,2013,104(9) :1211 - 1216.
  • 8Asnaeios A, Fartoux L, Romano O, et al. Gemcitabine plus oxali- platin (GEMOX) combined with cetuximab in patients with pro- gressive advanced stage hepatocellular carcinoma : results of a mul- ticenter phase 2study[ J]. Cancer,2008,112 (12) :2733 - 2739.
  • 9古伟光,谢忠,廖思海,罗海涛.吉西他滨联合草酸铂治疗晚期胆管癌的临床观察[J].现代肿瘤医学,2009,17(8):1520-1521. 被引量:7
  • 10岳原亦,张扬,张一奇.Caspase家族与细胞凋亡[J].中国医疗前沿,2011,6(6):25-26. 被引量:92

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部